Micro<scp>RNA</scp>‐622 is a novel mediator of tumorigenicity in melanoma by targeting Kirsten rat sarcoma

Dietrich, Péter; Kuphal, Silke; Spruß, Thilo; Hellerbrand, Claus; Bosserhoff, Anja‐Katrin

doi:10.1111/pcmr.12698

Cited by 20 publications

(28 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several miRNAs have been described recently as emerging and crucial KRAS regulators in different cancer types [162,163]. In another study, KRAS was shown by our group to be majorly regulated by miR-622 in melanoma [5]. Furthermore, acquired resistance to BRAF inhibitors in melanoma was dependent on dynamic regulation of KRAS expression and could be overcome by KRAS inhibition.…”

Section: Microrna-622mentioning

confidence: 80%

“…Furthermore, acquired resistance to BRAF inhibitors in melanoma was dependent on dynamic regulation of KRAS expression and could be overcome by KRAS inhibition. This highlights the strong and potential therapeutic impact of the miR-622-KRASaxis in melanoma [5,118]. MiR-622 is a strongly downregulated tumor-suppressive miRNA in melanoma, HCC and also in other cancer types.…”

Section: Microrna-622mentioning

confidence: 89%

“…The discovery of RNA-interference (RNAi), a mechanism mediated by one specific family of those non-coding RNAs-so-called microRNAs (miRNAs, miRs)-was groundbreaking [2,3]. MiRNAs are involved in the regulation of all major cellular processes, including proliferation, apoptosis, cell-cycle regulation and differentiation [3][4][5][6][7][8]. Until today, more than 1800 miRNA sequences have been discovered in the human genome [9] and these Figure 1.…”

Section: The Emerging Role Of Mirnas As Therapeutic Targets In Cancermentioning

confidence: 99%

“…One of the first miRNAs that was shown to be strongly associated with cancer development was let-7, regulating the expression of the potent oncogene rat sarcoma (RAS) [117]. RAS proteins including the isoforms KRAS and NRAS are amongst the most prominent oncogenes and were recently described to play major roles also in melanoma [5,118] and HCC [109,119,120]. Let-7 represents a highly conserved family of miRNAs [121].…”

Section: The Let-7 Mirna Familymentioning

confidence: 99%

“…Furthermore, cancer associated downregulation of let-7 results in reduced oxidative phosphorylation, glycolysis and production of ROS [94]. Downregulation of miR-622 results in an increase of its target KRAS [5,109]. KRAS can also interfere with the apoptosis pathway via upregulation of BCL-XL [109].…”

Section: The Let-7 Mirna Familymentioning

confidence: 99%

See 4 more Smart Citations

Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma

Linck-Paulus

Hellerbrand

Bosserhoff

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

In this review, we summarize the current knowledge on miRNAs as therapeutic targets in two cancer types that were frequently described to be driven by miRNAs—melanoma and hepatocellular carcinoma (HCC). By focusing on common microRNAs and associated pathways in these—at first sight—dissimilar cancer types, we aim at revealing similar molecular mechanisms that are evolved in microRNA-biology to drive cancer progression. Thereby, we also want to outlay potential novel therapeutic strategies. After providing a brief introduction to general miRNA biology and basic information about HCC and melanoma, this review depicts prominent examples of potent oncomiRs and tumor-suppressor miRNAs, which have been proven to drive diverse cancer types including melanoma and HCC. To develop and apply miRNA-based therapeutics for cancer treatment in the future, it is essential to understand how miRNA dysregulation evolves during malignant transformation. Therefore, we highlight important aspects such as genetic alterations, miRNA editing and transcriptional regulation based on concrete examples. Furthermore, we expand our illustration by focusing on miRNA-associated proteins as well as other regulators of miRNAs which could also provide therapeutic targets. Finally, design and delivery strategies of miRNA-associated therapeutic agents as well as potential drawbacks are discussed to address the question of how miRNAs might contribute to cancer therapy in the future.

show abstract

Section: Microrna-622mentioning

confidence: 80%

Section: Microrna-622mentioning

confidence: 89%

Section: The Emerging Role Of Mirnas As Therapeutic Targets In Cancermentioning

confidence: 99%

Section: The Let-7 Mirna Familymentioning

confidence: 99%

Section: The Let-7 Mirna Familymentioning

confidence: 99%

See 3 more Smart Citations

Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma

Linck-Paulus

Hellerbrand

Bosserhoff

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

Retracted: Deep integrative analysis of microRNA‐mRNA regulatory networks for biomarker and target discovery in chondrosarcoma

Sui

Liu

Zhang

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Chondrosarcoma (CHS) is a common malignant bone sarcoma and its occurrence increases with age. microRNAs (miRNAs) are a class of noncoding RNAs that participate in various biological processes and disease pathogenesis by targeting functional messenger RNA (mRNA). However, the modulation of miRNAs in CHS remains largely unknown. In this study, we performed integrative analysis to explore the expression profiles of miRNAs and mRNAs, together with their interaction networks in human CHS tissues and cell lines by RNA-seq (miRNA and mRNA). A total of 133 and 796 differentially expressed miRNAs and mRNAs were identified (|Fold change| ≥ 2 and P-value ≤ 0.5). miRNA-mRNA regulatory interactions between 55 miRNAs and 242 mRNAs were screened by the Pearson correlation analysis and target prediction. mRNAs in the network were enriched to 145 Gene Ontology terms and 35 Kyoto Encyclopedia of Genes and Genomes pathways. Specifically, some key regulators (hub-miRNAs) in the network (miR-622, miR-4539, miR-145, miR-25, and miR-96) were suggested to play important regulatory roles in the pathogenesis of CHS. In addition, functional experiments validated that miR-622 regulated CHS cell proliferation by targeting bone morphogenetic protein 1 (BMP1). K E Y W O R D S chondrosarcoma (CHS), miR-622, pearson correlation analysis, proliferation J Cell Biochem. 2019;120:9631-9638.wileyonlinelibrary.com/journal/jcb

show abstract

A novel circular RNA, hsa-circ-0000211, promotes lung adenocarcinoma migration and invasion through sponging of hsa-miR-622 and modulating HIF1-α expression

Feng

et al. 2020

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

MicroRNA‐622 is a novel mediator of tumorigenicity in melanoma by targeting Kirsten rat sarcoma

Cited by 20 publications

References 71 publications

Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma

Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma

Retracted: Deep integrative analysis of microRNA‐mRNA regulatory networks for biomarker and target discovery in chondrosarcoma

A novel circular RNA, hsa-circ-0000211, promotes lung adenocarcinoma migration and invasion through sponging of hsa-miR-622 and modulating HIF1-α expression

Contact Info

Product

Resources

About